Lanapave: New Anti-HIV Drug with 99.9% Efficacy Launched

As 2025 approaches, Gilead has welcomed an exciting start. The latest announcement from the official website of the National Medical Products Administration (NMPA) in China has confirmed that Gilead's application for marketing approval for its new 5.1 class drugs—Lanapave Tablets and Lanapave Injection—has been approved. These two drugs will be used in combination with other antiretroviral medications to treat adults with multi-drug resistant HIV infections.

Notably, Lanapave recently received the honor of being recognized as a "Top Scientific Breakthrough." On December 12, 2024, Science magazine announced its annual list of the top ten scientific breakthroughs, and Lanapave won the "Champion of Scientific Breakthroughs" award. This drug requires only a single injection to reduce the risk of HIV infection to zero within six months.

The results of the Phase 3 clinical trial PURPOSE 1 (targeting young women) released by Gilead indicate that Lanapave demonstrated 100% efficacy in preventing HIV in women. Similarly, the Phase 3 results of trial PURPOSE 2 (targeting diverse sexual populations) also showed that up to 99.9% of participants did not contract HIV after using Lanapave injections.

Based on these remarkable clinical data, researchers believe that Lanapave, as pre-exposure prophylaxis (PrEP), can protect millions of people from HIV infection, with the hope of making AIDS—a disease that once posed a serious threat to society—become increasingly rare.

The emergence of Lanapave not only signifies a significant scientific breakthrough but also indicates that it will become an important growth driver for Gilead in 2025. At this year's China International Import Expo, Sina Pharmaceuticals had the privilege of interviewing Professor Zhang Fuzhen from the Beijing Ditan Hospital affiliated with Capital Medical University. In the interview, Professor Zhang pointed out that the increasing risk of drug resistance is a major challenge in AIDS prevention and control. The emergence of drug resistance is related to multiple factors, including patients' non-compliance, insufficient drug dosages, cross-resistance, and the presence of resistant strains at initial infection. Professor Zhang emphasized that it is difficult for patients to adhere to regular medication, which is closely linked to the emergence of resistance.

The complexity and side effects of traditional AIDS treatment regimens have led some patients to discontinue their treatment. However, with advancements in technology, antiretroviral medications have been improved, reducing the need from taking three pills daily to just one. Even so, the psychological burden of long-term medication can still lead to irregular treatment. The advent of long-acting drugs significantly improves patient adherence; with injections twice a year, the frequency of medication use is greatly reduced, which may have historic significance for long-term prevention in the absence of a vaccine.

According to a report by Frost & Sullivan, the global market for antiretroviral drugs is expected to reach $47.9 billion by 2025 and grow to $57.5 billion by 2030. The compound annual growth rate (CAGR) from 2021 to 2025 is projected to be 6.0%, while the CAGR from 2025 to 2030 is anticipated to be 3.7%. In the new year, Gilead's second growth curve is about to take off.